EastPharma is a pharmaceutical company specialising in the manufacturing and marketing of branded generic pharmaceuticals in selected emerging markets, with a significant presence in Turkey.

Our manufacturing plants are located in Turkey, one of the world’s fastest growing generic pharmaceutical markets, and we sell our products at present to over twenty countries.

EastPharma was established on 17 August 2006 and controls Deva, a leading Turkish generic pharmaceutical company and Turkish pharmaceutical manufacturer Saba, in Turkey. EastPharma had a unit market share in Turkey in terms of units sold of 4.9 % as of 30 September 2008 in the human pharmaceuticals segment.

Deva and Saba specialise in the production and marketing of human pharmaceuticals, active pharmaceutical ingredients (API) and veterinary products. These core operations are supported by our consumer goods business lines, which includes empty glass ampoule and hygienic products manufacturing. As of 31 August 2008, EastPharma employed a total of 1,951 employees, mainly located in Turkey.

EastPharma’s organic growth strategy is to continue its growth in Turkey, to boost exports to selected emerging markets and to begin exporting to fully regulated markets in 2008. EastPharma is also seeking to acquire pharmaceutical companies in Turkey and selected emerging markets including Russia, Ukraine, the CIS and certain countries in North Africa and the Middle East which have complementary product portfolios and which can be used to penetrate markets in which EastPharma’s presence is still low.

EastPharma has four business lines:

Human Pharmaceuticals (approximately 83% of revenues in 1H 2008)
APIs (approximately 7%)
Veterinary Products (approximately 7%)
Consumer Goods (approximately 3%).

These business lines represent 105 pharmaceutical molecules in 244 pharmaceutical forms. Of these, 14 molecules are licensed molecules in 22 presentation forms.

The Human Pharmaceutical business line is supported by a strong sales force, which we believe is one of the largest and best trained in the Turkish pharmaceutical market. Our sales force comprises around 1000 medical and sales representatives.

We currently operate seven manufacturing plants at four factory sites with two more plants scheduled to start production at the end of 2008. All our factories are located near Istanbul.

We have two operational production units at the Çerkezköy factory, which is located in the west of Istanbul. These are a new, state-of-the-art penicillin production building, specializing in the production of penicillin in both oral dosage and injectable forms. This unit was inaugurated on 22 September, 2008, on the day that marked the 50th anniversary of Deva Holding. Another unit at Cerkezkoy produces amorph and coated form of Cefuroxime Axetil.

Two more new production units are currently under final construction at Cerkezkoy. These are a dedicated cephalosporin production unit and a general production unit for oral forms, syrups and ointments. The new cephalosporin unit is scheduled to start commercial production in November 2008 and the new general production unit is scheduled to open in December 2008. Cerkezkoy has a new automated warehouse with a 7,000 pallet capacity. The manufacturing facilities at Cerkezkoy occupies 31.000 m2 of indoor manufacturing floor space within an overall area of 51.000 m2.

The two factories in Köseköy in the east of Istanbul have four manufacturing units: a recently built new sterile manufacturing plant for parenterals and one for APIs and a production unit each for manufacturing empty glass ampoules and hygienic products, respectively. The Topkapi factory site in Istanbul produces medicines for human consumption as well as veterinary products.

The manufacturing facilities in Cerkezkoy together with the new injectables unit at the Kosekoy factory will increase Deva’s production capacity to more than 300 million boxes a year, more than threefold compared to production levels in 2007.

The new manufacturing facilities represent the most significant increase in production capacity since the company was established. These investments are an important milestone in the company's development, since the establishment of EastPharma as its main shareholder in 2006.

EastPharma shares are traded on the London Stock Exchange under the symbol ''EAST''.